Synthetic llama antibodies used to rescue mutated proteins
Engineered deubiquitinases combines a synthetic nanobody that recognises a protein that can rescue proteins tagged for destruction.
List view / Grid view
Engineered deubiquitinases combines a synthetic nanobody that recognises a protein that can rescue proteins tagged for destruction.
Next-generation sequencing will be employed to study 1,500 plasma proteins in participants, according to UK Biobank.
Study suggests reducing the expression of the methyl-CpG-binding domain 2 (MBD2) protein on macrophages could be a viable therapeutic strategy for lung fibrosis.
Scientists suggest that research using XPSCs, an intermediate form of embryonic stem cell, could help accelerate the development of stem cell-derived tissues and organs for transplantation.
A team has found that their drug Molnupiravir (MK-4482/EIDD-2801) acts as an antiviral against SARS-CoV-2 in pre-clinical studies.
Researchers show that neutralising antibodies targeting the SARS-CoV-2 Spike protein have four distinct structures.
Researchers have developed a novel insulin molecule that responds to glucose levels in the blood sugar of rats, which they say could help patients with type 1 diabetes.
Researchers show how genetically engineered five-module chimeric antigen receptor (5MCAR) T cells can be directed to destroy T cells causing autoimmune diseases.
The new study shows how SARS-CoV-2 significantly remodels cellular processes in just an hour and identifies potential drug targets and therapeutics for COVID-19.
A new technique using CRISPR has been developed by researchers to identify programmed stem cells that mature into neuronal cells.
Researchers report that their LEAPS COV-19 peptides significantly improved survival in a murine model of COVID-19.
According to new research, the protein ALDH4A1 is a possible therapeutic target and diagnostic biomarker for cardiovascular disease.
The novel probes, known as positive controls, could make it easier to validate rapid, point-of-care diagnostic tests for COVID-19 across the globe.
According to researchers, the more small tau protein variants expressed by neurons, the slower neurofibrillary tangles form.
Researchers have shown that the presence of the inflammasome mediated by NLRP3 is a marker and drug target for COVID-19-related cytokine storms.